The administration yesterday issued an interim final rule requiring health plans to begin submitting annual information next year on prescription drug coverage and spending, including the most frequently dispensed and costliest drugs, and information on prescription drug rebates and their impact on premiums and out-of-pocket spending. The rule also requires health plans and issuers to report on total spending for health care services by type (e.g., hospital care, primary care, specialty care, prescription drugs and other medical costs, including wellness services); and premium and prescription drug spending by employers versus employees. The departments of Health and Human Services, Labor and Treasury will use the data to issue biennial reports on prescription drug pricing trends and the impact of prescription drug costs on premiums and out-of-pocket costs starting in 2023. 

Related News Articles

Headline
The Trump administration today announced steps drug manufacturers must take to lower prescription drug prices in the U.S. to "most favored nation" pricing, the…
Headline
The Department of Health and Human Services today issued a notice announcing a 340B Rebate Model Pilot Program as a voluntary mechanism for qualifying drug…
Headline
The House has begun consideration of the Senate-passed version of the One Big Beautiful Bill Act (H.R. 1). This continues to be a fluid…
Headline
The AHA today commented to House and Senate appropriations committee leaders on funding for health care programs in the fiscal year 2026 appropriations bill.…
Headline
The Department of Health and Human Services May 20 announced it has identified specific pricing targets for pharmaceutical manufacturers to meet to satisfy…
Headline
The Centers for Medicare & Medicaid Services May 12 released draft guidance for the third round of negotiations for the Medicare Drug Price Negotiation…